RemeGen Receives Orphan Drug Designation from FDA for Telitacicept for the Treatment of Myasthenia Gravis

/PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced that the U.S. Food...

Related Keywords

China ,Yantai ,Shandong ,United States ,Chinese ,Jianmin Fang ,China National Medical Products Administration ,National Rare Diseases Registry System ,Remegen Co Ltd ,Drug Administration ,Remegen Co ,Prnewswire Remegen Co Ltd ,Chief Scientific Officer ,Brand Name ,National Medical Products Administration ,Looking Statements ,Td ,